CDI In the News

Madison, WI | May 19, 2026 – FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human-induced pluripotent stem cells (iPSCs), today celebrated the opening of its new headquarters and iPSC development and manufacturing facility in its Madison home. The new site is expected to quadruple the capacity for the company’s iPSC-based research products and services manufacturing footprint and expand capabilities across FUJIFILM Cellular Dynamics’ research product portfolio. With an eye toward future demand for contract manufacturing of cell therapy products, the facility is designed to be scalable to accommodate a wide range of processes, from investigational drug manufacturing to commercial production.

MADISON, Wis., September 10, 2024 – FUJIFILM Cellular Dynamics, a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs) today announces the global commercial launch of its human iPSC-derived iCell® Sensory Neurons for scientists engaged in neuroscience research, drug discovery of novel pain medications, and analysis of neurotoxicity side effects. FUJIFILM Cellular….

MADISON, Wisc., September 3, 2024 – FUJIFILM Cellular Dynamics and Opsis Therapeutics congratulate BlueRock Therapeutics on receiving FDA clearance of its IND application for OpCT-001, an induced pluripotent stem cell (iPSC)-derived cell therapy candidate for the treatment of primary photoreceptor diseases. OpCT-001 is the first iPSC therapy candidate licensed from the strategic research and development alliance….

CAMBRIDGE, Mass., May 30, 2024 – Fujifilm Life Sciences Strategic Business Office, with a portfolio of businesses offering products, services and comprehensive solutions that span support for all stages of therapeutic development from discovery through to commercialization, announces that it will showcase its offerings at booth 5035/4835 during the BIO International Convention (June 3-6), at….

FUJIFILM to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities TOKYO, December 4, 2023 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces the investment of USD 200 million in two subsidiaries to significantly expand global cell therapy contract development and manufacturing (CDMO) capabilities. The investment will enable….